Ballentine Partners LLC Has $1.45 Million Stock Position in Sanofi (NASDAQ:SNY)

Ballentine Partners LLC raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 68.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,063 shares of the company's stock after purchasing an additional 10,617 shares during the period. Ballentine Partners LLC's holdings in Sanofi were worth $1,445,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sanofi by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company's stock valued at $7,328,000 after acquiring an additional 12,440 shares during the period. Wealthfront Advisers LLC bought a new position in shares of Sanofi during the fourth quarter valued at $1,908,000. HighTower Advisors LLC lifted its holdings in shares of Sanofi by 3.4% during the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company's stock valued at $4,392,000 after acquiring an additional 2,971 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Sanofi by 2.1% during the fourth quarter. Sequoia Financial Advisors LLC now owns 21,003 shares of the company's stock valued at $1,013,000 after acquiring an additional 425 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on SNY. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reissued a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Morgan Stanley set a $56.00 price objective on Sanofi in a report on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Stock Performance

Sanofi stock traded down $0.73 during mid-day trading on Friday, hitting $48.61. 1,207,445 shares of the company's stock traded hands, compared to its average volume of 2,330,352. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The stock has a market cap of $119.21 billion, a price-to-earnings ratio of 17.36, a P/E/G ratio of 1.11 and a beta of 0.48. The firm has a 50 day simple moving average of $50.05 and a two-hundred day simple moving average of $52.11. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the firm earned $1.78 earnings per share. The company's revenue was down 11.0% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.